Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kodiak Sciences ( (KOD) ) has issued an update.
On June 2, 2025, Kodiak Sciences Inc. held its 2025 Annual Meeting of Stockholders where 82.20% of total shares entitled to vote were represented. During the meeting, Richard S. Levy, M.D., and Robert A. Profusek, J.D., were elected as Class I directors, the compensation of named executive officers was approved, and PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (KOD) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Kodiak Sciences stock, see the KOD Stock Forecast page.
Spark’s Take on KOD Stock
According to Spark, TipRanks’ AI Analyst, KOD is a Underperform.
Kodiak Sciences faces significant financial challenges with no revenue and substantial losses, placing it at the lower end of the scoring range. Its technical indicators show short-term positive momentum, but with caution due to overbought signals and broader downtrend pressures. The valuation reflects the typical high-risk, high-reward scenario of early-stage biotech firms.
To see Spark’s full report on KOD stock, click here.
More about Kodiak Sciences
Kodiak Sciences Inc. operates in the biotechnology industry, focusing on developing therapies for retinal diseases.
Average Trading Volume: 419,046
Technical Sentiment Signal: Sell
Current Market Cap: $189.9M
See more insights into KOD stock on TipRanks’ Stock Analysis page.